Gold-Induced Cytokine (GOLDIC®) Therapy in the Management of Knee Osteoarthritis: An Observational Study
Cureus · 29.09.2023
DOI: 10.7759/cureus.46231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 29.09.2023. Verfasst von Sharmila Tulpule und 5 weiteren Autor:innen. Beteiligte Einrichtung: Orthopaedics and Regenerative Medicine, Orthobiologix Clinic, Mumbai, IND. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Current treatment modalities for knee osteoarthritis (OA) provide symptomatic cures rather than reversing the pathology in the long term. An innovative regenerative therapy called "Gold Induced Cytokines" (GOLDIC®) was explored in various musculoskeletal diseases such as knee OA, lumbar canal stenosis, Achilles tendinopathy, and plantar fasciitis. In this study, we explored the safety and functional outcome of GOLDIC® injections in knee OA (KL grades 3 and 4) with visual analog scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. MATERIALS AND METHODS: A multi-center open-label observational study was carried out after screening the cases according to the inclusion criteria. A total of 106 knees in 65 patients were enrolled for four doses of 4 ml of ultrasound-guided intra-articular GOLDIC® injections every three to six days. All cases were followed up with pre- and post-VAS and WOMAC scores at an interval of four weeks, three months, six months, and one year, and the complications (including severe adverse reactions) were monitored throughout. RESULTS: In this study, 66.1% had grade 4 OA knee (without gross varus or subluxation) and 33.8% had grade 3 OA knee. All the participants underwent the GOLDIC® treatment modality. A statistically significant difference was observed in pre- and post-procedural follow-up in VAS and WOMAC scores at one-year follow-up. There were no recorded severe adverse reactions during the entire study period. Three patients failed the treatment in one year. CONCLUSION: The GOLDIC® procedure shows great promise as a novel method for treating moderate to severe OA of the knee, both in terms of pain and functional outcome without any severe adverse reactions, in a sustained manner and is worth exploring as a long-term treatment option.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Orthopaedics and Regenerative Medicine, Orthobiologix Clinic, Mumbai, IND.
- Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, IND.
- Orthopaedics, KIMS-Sunshine Hospital, Hyderabad, IND.
- Clinical Pathology, Infohealth FZE, Dubai, ARE.
- Internal Medicine, Shri Madan Lal Khurana Chest Clinic, New Delhi, IND.
Zitieren
APA
Tulpule, S., Jeyaraman, M., Jayakumar, T., Jeyaraman, N., Bapat, A., & Yadav, S. (2023). Gold-Induced Cytokine (GOLDIC®) Therapy in the Management of Knee Osteoarthritis: An Observational Study. Cureus. https://doi.org/10.7759/cureus.46231
Vancouver
Tulpule S, Jeyaraman M, Jayakumar T, Jeyaraman N, Bapat A, Yadav S. Gold-Induced Cytokine (GOLDIC®) Therapy in the Management of Knee Osteoarthritis: An Observational Study. Cureus. 2023. doi:10.7759/cureus.46231
BibTeX
@article{Tulpule2023,
author = {Tulpule, Sharmila and Jeyaraman, Madhan and Jayakumar, Tarun and Jeyaraman, Naveen and Bapat, Asawari and Yadav, Sankalp},
title = {Gold-Induced Cytokine (GOLDIC®) Therapy in the Management of Knee Osteoarthritis: An Observational Study},
journal = {Cureus},
year = {2023},
doi = {10.7759/cureus.46231}
}
EUVIMED